Molecular alterations of the TLR4-signaling cascade in canine epilepsy

Eva-Lotta von Rüden1, Fabio Gualtieri1, Katharina Schönhoff1

  • 1Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University (LMU), Königinstr. 16, D-80539, Munich, Germany.

BMC Veterinary Research
|January 22, 2020
PubMed
Abstract

Insights

Inflammatory signaling via Toll-like receptor-4 is altered in canine epilepsy. Specific receptor and ligand changes were observed in different epilepsy types and brain regions, suggesting potential therapeutic targets.

Area of Science:

  • Neuroscience
  • Immunology
  • Veterinary Medicine

Background:

  • Rodent models suggest inflammatory signaling, particularly Toll-like receptor-4 (TLR4), plays a role in epilepsy.
  • Limited data exists on TLR4 pathway alterations in canine epilepsy.
  • This study investigates TLR4 and its ligand expression in canine epilepsy.

Purpose of the Study:

  • To analyze the expression patterns of Toll-like receptor-4 and its ligands in canine epilepsy.
  • To compare these expression patterns between structural epilepsy, idiopathic epilepsy, and control dogs.
  • To identify potential molecular targets for managing canine epilepsy.

Main Methods:

  • Analysis of brain tissue from dogs with structural epilepsy, idiopathic epilepsy, and healthy controls.
  • Quantitative assessment of Toll-like receptor-4 and its ligands (HMGB1, HSP70) expression.
  • Comparison of expression levels across different brain regions (CA1, CA3, piriform lobe).

Main Results:

  • Overexpression of Toll-like receptor-4 in the CA3 region of dogs with structural epilepsy.
  • Upregulation of Toll-like receptor-4 ligands: HMGB1 in CA1 (idiopathic and structural epilepsy), HSP70 in the piriform lobe (idiopathic epilepsy).
  • Other brain regions showed receptor and ligand expression at or below control levels.

Conclusions:

  • Complex molecular alterations in the Toll-like receptor signaling cascade are present in canine epilepsy.
  • These alterations vary by epilepsy type and brain region.
  • Modulating Toll-like receptor-4 signaling may offer therapeutic potential for canine epilepsy management.